Reduced financial support / philanthropy
|
Limited donations given personal budget constraints or loss of revenues
from in person event cancellations and economic uncertainties
|
Less resources to offer patients and families, less funding for
treatment and non-treatment related expenses
New programs delayed or cancelled
Grant opportunities reduced, delayed or cancelled
|
New patients not recruited to sponsored clinical trials
|
Resources diverted to COVID-19
Perceived risk to patients
|
Increased anxiety and fear among patients and families
Reduced options for treatment of relapsed/refractory disease, potential
reduction in overall survival
|
Sponsored programs delayed or cancelled
|
Research and development resources diverted
Research labs closed
Workers furloughed
|
Pressure from donors and supporters to move programs forward
Unanticipated additional costs
|
Reduced community engagement |
Community focus on COVID-19 |
Reduced
philanthropy |
Limitations in available housing and transportation |
Restrictions in
place from COVID-19 |
Impact on clinical care |
Reduced lobbying for pediatric cancer |
Government focus on COVID-19 |
Less government awareness and earmarked funding |
National and international pediatric oncology meetings cancelled or
postponed |
Missed opportunities for engagement with other stakeholders |
Collaborative partnerships not developed |